1.Hansen DK, et al. Comparison of Time to Next Treatment or Death between Front-Line Daratumumab, Lenalidomide, and Dexamethasone (DRd) and Bortezomib, Lenalidomide, and Dexamethasone (VRd) in Transplant Ineligible Pati...
11. Medhekar R, et al. Real-world patient characteristics and treatment outcomes among nontransplanted multiple myeloma patients who received Bortezomib in combination with Lenalidomide and Dexamethasone as first line of therapy in...
ground:Both daratumumab in combination with lenalidomide and dexamethasone (DRd) and bortezomib in combination with lenalidomide and dexamethasone (VRd) are endorsed by NCCN guidelines as preferred regimens for the treatment of transplant-ineligible (TIE) patients with newly diagnosed multiple myeloma (...
Corporation Income Tax Return, do not tie neatly to the new federal schedules that include this income and then provide for deductions; and the states are concerned about double-dipping: "Oh no, you get to deduct the 50% of GILTI and take a DRD at the same time?" States' treatment of...
Conclusion : This updated analysis reveals that DRd provided clinical benefit to patients regardless of prior treatment history, cytogenetic risk or moderate renal impairment. This analysis demonstrates that DRd should be considered after lenalidomide-based therapies in patients with RRMM, including those ...
For PFS on subsequent line of therapy (PFS2; defined as time from randomization to progression after next line of subsequent therapy or death) was examined as an exploratory endpoint. Results: Pts in both treatment groups (DRd, n=286; Rd, n=283) received a median of 1 prior line of ...
DRd Superior to Rd Regardless of Time Since Last Therapy in MyelomaJason HoffmanPharmD